Bristol-Myers Squibb (BMY) announced after the bell Wednesday that it has suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase inhibitor in development for the treatment of hepatitis C.
Bristol-Myers Squibb gapped open sharply lower Thursday and slipped further during the second half of the session. The stock closed down by 3.05 at $32.55 on the highest volume of the year and fell to over a 2-month low.
For comments and feedback: editorial@rttnews.com